California-based Sonoma Pharmaceuticals (Nasdaq:SNOA) has received approval from the US Food and Drug Administration (FDA) for their antimicrobial post-therapy gel.
Shares of the company soared this morning after the announcement and, currently, the high for Sonoma Pharmaceuticals has been $4.80 USD.
This is the highest shares have been since the beginning of February 2018, where the company closed at $4.86 USD.
>>>Best Pharma Stocks: Cascadian Therapeutics Up Over 70%
The gel is said to help relieve itching and pain that is associated with post-laser therapy procedures, from minor skin irritations to lacerations, abrasions and minor burns.
In 2013, US dermatologists and surgeons performed up to 2.25 million laser, light, and energy-based procedures, with a total 22% increase of all medical and aesthetic skin procedures from the previous year.
According to Dr. Michael Gold, a certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Research Center, all located in Nashville, Tennessee, has said “this antimicrobial post-treatment gel is a promising new tool for all dermatologists and aesthetic clinicians who are looking to better manage medical procedures, post-procedure itch and pain associated with procedures including laser skin resurfacing, while promoting enhanced healing and protection against secondary infections.”
>>>Dermira Stocks Plunge 65% Over Drug Failure
Sonoma Pharmaceuticals CEO, Jim Schutz, has said that the recent approval from the FDA “is one in a series that further fortifies Sonoma’s portfolio of innovative antimicrobial dermatology products.”
The company currently has several products available that focus on helping to manage skin conditions such as eczema, psoriasis, acne, and scars.
Although Sonoma’s shares have risen there looks to be a slight downward trend. The company is still at nearly +14.5%, but that is less than what the company had when the market opened.
Featured Image: Facebook
